Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023PRNewsWire • 07/20/23
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare ConferencePRNewsWire • 06/05/23
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SPRNewsWire • 06/02/23
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion SicknessPRNewsWire • 05/25/23
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential InformationPRNewsWire • 05/02/23
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023PRNewsWire • 04/27/23
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsPRNewsWire • 02/08/23
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023PRNewsWire • 02/01/23
Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launchPRNewsWire • 12/16/22
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance AnxietyPRNewsWire • 12/02/22
Vanda Pharmaceuticals Announces Participation at November 2022 Investor ConferencesPRNewsWire • 11/09/22